Corning Incorporated (NYSE: GLW) today announced that a leading pharmaceutical manufacturer has received FDA approval of Corning Valor® Glass for use as a primary package for a marketed drug product.
Valor Glass has been specifically designed for pharmaceutical applications, and this approval makes Valor Glass the first and only fundamentally new glass composition to be approved by the FDA since the advent of borosilicate glass more than 100 years ago.
This innovative glass packaging solution has been designed to enable superior chemical durability and improve resistance to breakage, damage, and particulate contamination. These attributes can help enhance manufacturing productivity by enabling increased throughput and quality assurance for pharmaceutical manufacturers.
“We are thrilled to reach this important milestone. This modernization of glass packaging was made possible through our strong customer relationships and our shared passion for life-changing innovations,” said Wendell P. Weeks, Corning Incorporated chairman, chief executive officer, and president. “We would also like to recognize the members of the FDA’s Emerging Technology Team. Their strong support encourages the development and adoption of innovative technologies like Valor Glass.”
“We believe that Valor Glass is the future of parenteral glass packaging for manufacturers. This FDA approval is an important first step on our journey to create a new standard in pharmaceutical glass packaging. It’s great news for patients, for the industry, and for Corning,” added Ronald Verkleeren, vice president and general manager, Corning Pharmaceutical Technologies
